Clincosm LogoSign in Get a demo

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Sponsor
Hoffmann-La Roche (Industry)
Overall Status
Recruiting
CT.gov ID
NCT03075696
Collaborator
(none)
860
Enrollment
41
Locations
3
Arms
76.2
Anticipated Duration (Months)
21
Patients Per Site
0.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-to-human study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-participant dose-escalation cohorts will be used in Part I, followed by conversion to multiple participant dose-escalation cohorts (Part II), in order to define a tentative maximum tolerated dose (MTD) or optimal biological dose (OBD). The expansion cohorts (Part III) will be initiated when the tentative MTD/OBD is defined, to further evaluate the safety, PK and therapeutic activity of glofitamab.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
860 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Multicenter, Open-Label, Phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Actual Study Start Date :
Feb 21, 2017
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Part I: Dose Escalation

Participants (single participant cohorts) will receive obinutuzumab (Gpt) 1000 milligrams (mg) single dose IV infusion on Day -7 (pre-treatment) followed by glofitamab IV infusion on Day 1 and Day 8 of Cycle 1. From Cycle 2 onwards, ascending doses of glofitamab will be administered on Day 1 of every 2 week cycle up to Cycle 12 (24 weeks) or until unacceptable toxicity or disease progression. Glofitamab dosing will be initiated at 5 micrograms (mcg) (flat dose) followed by doses of 15 mcg, 45 mcg, 135 mcg, 405 mcg and 810 mcg.

Drug: Glofitamab
Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
Other Names:
  • RO7082859

    • Drug: Obinutuzumab
    Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
    Other Names:
  • RO5072759, GA101, Gazyva®, Gazyvaro™

    • Drug: Tocilizumab
    Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
    Other Names:
  • Actemra®, Roactemra®

    		•
    Experimental: Part II: Dose Escalation

    In each treatment regimen, participants will receive obinituzumab (Gpt) 1000 milligrams (mg) IV infusion on Day -7 (pre-treatment); or 2000 mg either administered on Day -7, or split into two 1000 mg doses on Days -1 and -7. The first glofitamab IV infusion will be given on Day 1 of Cycle 1 and a total of 12 cycles will be administered. Monotherapy, glofitamab as a single agent: ascending doses of glofitamab administered on Day 1 of every 2 or 3 week cycle until either the MTD/OBD is defined. Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with ascending doses of glofitamab on Day 1 of every 3 week cycle until either the MTD/OBD is defined. Step-up dosing: Q3W, participants will receive an initial low dose of glofitamab on C1D1, followed by a higher dose on C1D8; the total dose in C1 will not exceed the previously determined MTD. Higher doses may be explored from C2 or later cycles.

    Drug: Glofitamab
    Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
    Other Names:
  • RO7082859

    • Drug: Obinutuzumab
    Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
    Other Names:
  • RO5072759, GA101, Gazyva®, Gazyvaro™

    • Drug: Tocilizumab
    Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
    Other Names:
  • Actemra®, Roactemra®

    		•
    Experimental: Part III: Dose Expansion

    Part III will start once MTD/OBD is defined. Participants will receive Gpt 1000 mg single dose IV infusion on Day -7 (pre-treatment), followed by glofitamab at a fixed dose regimen or step-up dose regimen on a Q2W or Q3W dosing schedule as determined in Part II. A total of 12 cycles will be administered. Combination Therapy: From Cycle 2 onwards, a fixed dose of 1000 mg obinutuzumab will be administered via IV infusion in combination with glofitamab at the dosing regimen determined in Part II.

    Drug: Glofitamab
    Glofitamab will be administered at a dose and as per the schedule specified in the respective arms.
    Other Names:
  • RO7082859

    • Drug: Obinutuzumab
    Obinutuzumab 1000 mg single dose IV infusion on Day -7; or 2000 mg single dose administered on Day -7, or split into two 1000 mg doses administered on Days -1 and -7, and per the schedule specified in the respective arms.
    Other Names:
  • RO5072759, GA101, Gazyva®, Gazyvaro™

    • Drug: Tocilizumab
    Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of glofitamab, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
    Other Names:
  • Actemra®, Roactemra®

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Part I and II: Percentage of Participants With Dose Limiting Toxicities (DLTs) [From Baseline up to 4 weeks]

    2. Part I, II and III: Percentage of Participants With Adverse Events (AEs) [From Baseline up to 90 days after last dose of study drug or until study completion or participant withdrawal (up to 5 years)]

    3. Part II: MTD or OBD of Glofitamab [From Baseline up to 4 weeks]

    4. Part II: Recommended Phase II Dose (RP2D) of Glofitamab [From Baseline up to 5 years]

    5. Part III: Complete Response (CR) Rate as Assessed by Independent Review Committee (IRC) According to Standard Non-Hodgkin's Lymphoma (NHL) Response Criteria (Lugano Classification) [From treatment start up to 5 years]

    6. Part I, II and III: Area Under the Serum Concentration Versus Time Curve (AUC) of Glofitamab [At pre-defined intervals from Cycle 1 Day 1 to Day 71]

    7. Part I, II and III: Maximum Serum Concentration (Cmax) of Glofitamab [At pre-defined intervals from Cycle 1 Day 1 to Day 198]

    8. Part I, II and III: Minimum Serum Concentration (Cmin) of Glofitamab [At pre-defined intervals from Cycle 1 Day 1 up to Day 198]

    9. Part I, II and III: Clearance (CL) of Glofitamab [At pre-defined intervals from Cycle 1 Day 1 to Day 71]

    10. Part I, II and III: Volume of Distribution at Steady-State (Vss) of Glofitamab [At pre-defined intervals from Cycle 1 Day 1 to Day 71]

    11. Part I, II and III: Half-Life (t1/2) of Glofitamab [At pre-defined intervals from Cycle 1 Day 1 to Day 71]

    Secondary Outcome Measures

    1. Part I, II and III: Cmax of Obinutuzumab [Pre-dose of obinutuzumab on Day -7; pre-dose (Hr 0) of glofitamab on Day 1 of Cycle 1]

    2. Part I, II and III: Cmin of Obinutuzumab [Pre-dose of obinutuzumab on Day -7; pre-dose (Hr 0) of glofitamab on Day 1 of Cycle 1]

    3. Part I, II and III: Anti-Drug Antibodies (ADA) to Glofitamab [Pre-dose of obinutuzumab on Day -7; pre-dose (Hr 0) of glofitamab on Day 1 of each cycle from Cycle 2 onwards for a maximum of 8-12 cycles, and at EOT/follow-up visit (up to 5 years)]

    4. Parts I and II: Percentage of Participants With Overall Response (Partial Response [PR] or Complete Response [CR]) as Determined by the Lugano Classification [From Baseline up to end of study or discontinuation due to disease progression (up to 5 years)]

    5. Part I, II and III: Percentage of Participants With PR or CR (Overall Response Rate) as Determined by the Lugano Classifications [From Baseline up to end of study or discontinuation due to disease progression (up to 5 years)]

    6. Part I, II and III: Duration of Response (DOR) as Determined by the Lugano Classification [From first occurrence of documented objective response until disease progression, relapse or death due to any cause (up to 5 years)]

    7. Part I, II and III: Duration of Complete Response (DOCR) as Determined by the Lugano Classification [From the first occurrence of a documented, complete response, until the time of relapse or death from any cause (up to 5 years)]

    8. Part I, II and III: Progression-Free Survival (PFS) as Determined by the Lugano Classification [From first study treatment to the first occurrence of disease progression or death due to any cause (up to 5 years)]

    9. Overall Survival (OS) [From the time of first study treatment to death from any cause (up to 5 years)]

    10. Time to First Overall Response (TFOR) [From time of treatment start to first documented response (up to 5 years)]

    11. Time to First Complete Response (TFCR) [From treatment start to first documented complete response (up to 5 years)]

    12. Health Related Quality of Life (HRQoL) as Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) [From baseline through follow-up or until disease progression (up to 5 years)]

    13. HRQoL as Assessed by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Lymphoma Scale [From baseline through follow-up or until disease progression (up to 5 years)]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Depending upon study part, a history or status of: 1) a histologically-confirmed hematological malignancy that is expected to express cluster of differentiation (CD)20; 2) relapse after or failure to respond to at least one prior treatment regimen; and 3) no available treatment options that are expected to prolong survival (e.g., standard chemotherapy or autologous stem cell transplant [ASCT])

    • Measurable disease, defined as at lease one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or at least one bi-dimensionally measureable extranodal lesion, defined as > 1.0 cm in its longest dimension

    • Able to provide a fresh biopsy from a safely accessible site, per investigator determination, providing the patient has more than one measurable target lesion

    • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

    • Life expectancy of >/=12 weeks

    • AEs from prior anti-cancer therapy must have resolved to Grade less than or equal to (</=) 1

    • Adequate liver, hematological and renal function

    • Negative serologic or polymerase chain reaction (PCR) test results for acute or chronic Hepatitis B virus (HBV) infection

    • Negative test results for Hepatitis C virus (HCV) and human immunodeficiency virus (HIV)

    • Negative serum pregnancy test within 7 days prior to study treatment in women of childbearing potential. Women who are not of childbearing potential who are considered to be post-menopausal (at least 12 months of non-therapy amenorrhea) or surgically sterile (absence of ovaries and/or uterus) are not required to have a pregnancy test

    Exclusion Criteria:

    • Inability to comply with protocol mandated hospitalizations and restrictions

    • Participants with chronic lymphocytic leukemia (CLL), Burkitt lymphoma and lymphoplasmacytic lymphoma

    • Participants with a known or suspected history of hemophagocytic lymphohistiocytosis (HLH)

    • Participants with acute bacterial, viral, or fungal infection at baseline, confirmed by a positive blood culture within 72 hours prior to obinutuzumab infusion or by clinical judgment in the absence of a positive blood culture

    • Participants with known active infection, or reactivation of a latent infection, whether bacterial, viral, fungal, mycobacterial, or other pathogens or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of dosing

    • Prior treatment with systemic immunotherapeutic agents, including, but not limited to, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines and monoclonal antibodies (e.g., anti-cytotoxic T-lymphocyte-associated protein 4 [anti-CTLA4], anti-programmed death 1 [anti-PD1] and anti-programmed death ligand 1 [anti-PDL1]) within 4 weeks or five half-lives of the drug, whichever is shorter, before obinutuzumab infusion on Cycle 1 Day -7

    • History of treatment-emergent immune-related AEs associated with prior immunotherapeutic agents

    • Documented refractoriness to an obinutuzumab-containing regimen

    • Treatment with standard radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent, including chimeric antigen receptor therapy (CAR-T) within 4 weeks prior to obinutuzumab infusion

    • Prior solid organ transplantation

    • Prior allogeneic SCT

    • Autologous SCT within 100 days prior to obinutuzumab infusion

    • Participant with history of confirmed progressive multifocal leukoencephalopathy (PML)

    • Current or past history of central nervous system (CNS) lymphoma

    • Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a past history of stroke that have not experienced a stroke or transient ischemic attack in the past 2 years and have no residual neurologic deficits are allowed.

    • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including diabetes mellitus, history of relevant pulmonary disorders and known autoimmune diseases

    • Participants with another invasive malignancy in the last 2 years (with the exception of basal cell carcinoma and tumors deemed by the Investigator to be of low likelihood for recurrence)

    • Significant or extensive history of cardiovascular disease such as New York Heart Association Class III or IV or Objective Class C or D cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina

    • Administration of a live, attenuated vaccine within 4 weeks before obinutuzumab infusion or anticipation that such a live attenuated vaccine will be required during the study

    • Received systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within two weeks prior to obinutuzumab infusion. Treatment with corticosteroid </= 25 mg/day prednisone or equivalent is allowed. Inhaled and topical steroids are permitted.

    • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug

    • History of autoimmune disease, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus, erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Participants with a remote history of, or well controlled autoimmune disease, may be eligible to enroll after consultation with the Medical Monitor

    • In Part III DLBCL dexamethasone cohort, patients with a history of hypersensitivity to dexamethasone or systemic corticosteroids will be excluded

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cedars Sinai Medical Center Los Angeles California United States 90048
    2 Ingalls Memorial Hospital Harvey Illinois United States 60426
    3 University of Kansas Medical Centre Kansas City Kansas United States 66160
    4 University of Michigan Ann Arbor Michigan United States 48109-0934
    5 Washington University; Wash Uni. Sch. Of Med Saint Louis Missouri United States 63110
    6 Mount Sinai Medical Center New York New York United States 10029
    7 MSKCC New York New York United States 10065
    8 Allegheny Health Network (Pittsburg PA) Pittsburgh Pennsylvania United States 15212
    9 Hunstman Cancer Institute Salt Lake City Utah United States 84112
    10 Virginia Commonwealth University Medical Center Richmond Virginia United States 23230
    11 Swedish Cancer Inst. Seattle Washington United States 98104
    12 Prince of Wales Hospital; Haematology Randwick New South Wales Australia 2031
    13 Peter Maccallum Cancer Centre Melbourne Victoria Australia 3000
    14 Cliniques Universitaires St-Luc Bruxelles Belgium 1200
    15 UZ Gent Gent Belgium 9000
    16 Princess Margaret Cancer Center Toronto Ontario Canada M5G 1Z5
    17 Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK Praha 2 Czechia 128 08
    18 Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT København Ø Denmark 2100
    19 Helsinki University Central Hospital; Dept of Oncology Helsinki Finland 00250
    20 Hopital Henri Mondor; Hematologie Clinique Creteil France 94010
    21 Hopital Claude Huriez; Hematologie Lille France 59037
    22 CHU Saint Eloi; Service d'Hématologie Clinique Montpellier France 34295
    23 Ch Lyon Sud; Hemato Secteur Jules Courmont Pierre Benite France 69495
    24 CHU DE RENNES - CHU Pontchaillou; Service d'Hématologie Clinique Adulte Rennes France 35033
    25 AUSL della Romagna; Dipartimento Oncoematologico - U.O.C. Oncologia Ravenna Emilia-Romagna Italy 48121
    26 Fond. IRCCS Istituto Nazionale Tumori; S. C. Ematologia Milano Lombardia Italy 20133
    27 Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia Rozzano Lombardia Italy 20089
    28 A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia Torino Piemonte Italy 10126
    29 Auckland Cancer Trial Centre; Ward 64, Auckland City Hospital, Auckland New Zealand 1023
    30 Uniwersyteckie Centrum Kliniczne; Osrodek Badan Wczesnych Faz Gdańsk Poland 80-214
    31 Szpital Kliniczny im. Heliodora Święcickiego; Oddzial Hematologii i Transplantacji Szpiku Poznań Poland 60-569
    32 Centrum Onkologii-Instytut im. M. Sklodowskiej-Curie; Oddzial Badan Wczesnych Faz Warszawa Poland 02-781
    33 Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Wrocław Poland 50-367
    34 Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia Badalona Barcelona Spain 08915
    35 Hospital Duran i Reynals L'Hospitalet; Hematology Department L'Hospitalet de Llobregat Barcelona Spain 08908
    36 Hospital Universitario Marques de Valdecilla; Servicio de Hematologia Santander Cantabria Spain 39008
    37 Hospital del Mar; Servicio de Hematologia Barcelona Spain 08003
    38 Hospital Universitari Vall d'Hebron; Servicio de Hematologia Barcelona Spain 08035
    39 Hospital Univ. 12 de Octubre; Servicio de Hematologia Madrid Spain 28041
    40 China Medical University Hospital; Oncology and Hematology Taichung Taiwan 404
    41 National Taiwan Universtiy Hospital; Division of Hematology Taipei Taiwan 100

    Sponsors and Collaborators

    • Hoffmann-La Roche

    Investigators

    • Study Director: Clinical Trials, Hoffmann-La Roche

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hoffmann-La Roche
    ClinicalTrials.gov Identifier:
    NCT03075696
    Other Study ID Numbers:
    • NP30179
    • 2016-001185-28
    First Posted:
    Mar 9, 2017
    Last Update Posted:
    Aug 11, 2022
    Last Verified:
    Aug 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Lymphoma
    Lymphoma, Non-Hodgkin
    Lymphoma, B-Cell
    Obinutuzumab

    Study Results

    No Results Posted as of Aug 11, 2022